Harmony to Begin Phase 3 Study of Pitolisant for Prader-Willi Syndrome

Harmony Biosciences Holdings Inc has completed an end-of-phase 2 meeting with the US Food and Drug Administration (FDA) regarding its clinical development plan evaluating pitolisant as a potential treatment for excessive daytime sleepiness in patients ages 6 and older with Prader-Willi syndrome. Harmony plans to initiate a phase 3 registrational study in the fourth quarter…

Read More

Symptoms of Idiopathic Hypersomnia

Sree Roy:  Hello, and welcome. I’m Sree Roy with Sleep Review, and I’m thrilled to be here with sleep specialist Logan Schneider, MD, who is skilled in clinical research, medical education, epidemiology, sleep medicine, and neurology. He received post-doctoral training in sleep genetics and big data and has advised multiple startups in their sleep endeavors.  …

Read More

Office for Disparities Research and Workforce Diversity Webinar Series: Advancing Mental Health Disparities Research Focused on Bi+ People Through an Intersectional Lens

Date and Time August 2, 202312:30–2:00 p.m. ET OverviewThe prevalence of mental health disparities is higher among bisexual and other multi-gender attracted (e.g., pansexual, queer; collectively “bi+”) individuals compared to monosexual (e.g., heterosexual, lesbian, gay) individuals. In the United States, the prevalence of mood/anxiety disorders is higher among bi+ women compared to heterosexual and lesbian women.…

Read More